Allemani Claudia, Harewood Rhea, Johnson Christopher J, Carreira Helena, Spika Devon, Bonaventure Audrey, Ward Kevin, Weir Hannah K, Coleman Michel P
Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Cancer Data Registry of Idaho, Boise, Idaho.
Cancer. 2017 Dec 15;123 Suppl 24(Suppl 24):4982-4993. doi: 10.1002/cncr.31025.
Robust comparisons of population-based cancer survival estimates require tight adherence to the study protocol, standardized quality control, appropriate life tables of background mortality, and centralized analysis. The CONCORD program established worldwide surveillance of population-based cancer survival in 2015, analyzing individual data on 26 million patients (including 10 million US patients) diagnosed between 1995 and 2009 with 1 of 10 common malignancies.
In this Cancer supplement, we analyzed data from 37 state cancer registries that participated in the second cycle of the CONCORD program (CONCORD-2), covering approximately 80% of the US population. Data quality checks were performed in 3 consecutive phases: protocol adherence, exclusions, and editorial checks. One-, 3-, and 5-year age-standardized net survival was estimated using the Pohar Perme estimator and state- and race-specific life tables of all-cause mortality for each year. The cohort approach was adopted for patients diagnosed between 2001 and 2003, and the complete approach for patients diagnosed between 2004 and 2009.
Articles in this supplement report population coverage, data quality indicators, and age-standardized 5-year net survival by state, race, and stage at diagnosis. Examples of tables, bar charts, and funnel plots are provided in this article.
Population-based cancer survival is a key measure of the overall effectiveness of services in providing equitable health care. The high quality of US cancer registry data, 80% population coverage, and use of an unbiased net survival estimator ensure that the survival trends reported in this supplement are robustly comparable by race and state. The results can be used by policymakers to identify and address inequities in cancer survival in each state and for the United States nationally. Cancer 2017;123:4982-93. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
基于人群的癌症生存估计的可靠比较需要严格遵守研究方案、标准化质量控制、合适的背景死亡率生命表以及集中分析。CONCORD项目于2015年建立了全球基于人群的癌症生存监测，分析了1995年至2009年间确诊的2600万患者（包括1000万美国患者）的个体数据，这些患者患有10种常见恶性肿瘤中的一种。
在本癌症增刊中，我们分析了参与CONCORD项目第二轮（CONCORD - 2）的37个州癌症登记处的数据，覆盖了约80%的美国人口。数据质量检查分三个连续阶段进行：方案依从性、排除和编辑检查。使用波哈尔·佩尔梅估计器以及每年按州和种族划分的全因死亡率生命表来估计1年、3年和5年年龄标准化净生存率。对2001年至2003年确诊的患者采用队列法，对2004年至2009年确诊的患者采用完整法。
本增刊中的文章报告了按州、种族和诊断阶段划分的人群覆盖情况、数据质量指标以及年龄标准化5年净生存率。本文提供了表格、柱状图和漏斗图的示例。
基于人群的癌症生存是衡量服务在提供公平医疗保健方面整体有效性的关键指标。美国癌症登记数据的高质量、80%的人口覆盖率以及使用无偏净生存估计器确保了本增刊中报告的生存趋势在种族和州之间具有可靠的可比性。这些结果可供政策制定者用于识别和解决每个州以及美国全国范围内癌症生存方面的不平等问题。《癌症》2017年；123:4982 - 93。2017年发表。本文为美国政府作品，在美国属于公共领域。
